NCT01506193View on ClinicalTrials.gov

Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

PHASE3CompletedINTERVENTIONAL
Enrollment

716

Participants

Timeline

Start Date

February 6, 2012

Primary Completion Date

February 17, 2014

Study Completion Date

March 31, 2014

Conditions
RubellaVaricellaMeaslesMumps
Interventions
BIOLOGICAL

PriorixTetra™

One dose administered subcutaneously

BIOLOGICAL

Meningitec

One dose administered intramuscularly

Trial Locations (13)

12100

GSK Investigational Site, Cuneo

16043

GSK Investigational Site, Chiavari

16132

GSK Investigational Site, Genoa

20122

GSK Investigational Site, Milan

20142

GSK Investigational Site, Milan

28100

GSK Investigational Site, Novara

95129

GSK Investigational Site, Catania

97100

GSK Investigational Site, Modica (RG)

GSK Investigational Site, Ragusa (RG)

00165

GSK Investigational Site, Rome

07041

GSK Investigational Site, Alghero (SS)

09127

GSK Investigational Site, Cagliari

07100

GSK Investigational Site, Sassari

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01506193 - Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children | Biotech Hunter | Biotech Hunter